A week after Pfizer unveiled a reshuffled team that'll report to incoming CEO Albert Bourla, the drug giant says it plans to trim its workforce.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

The FDA OPDP slapped a warning letter on Mannkind for failing to mention Afrezza's risks.

Allergan and Eli Lilly won coverage from PBM giant Express Scripts for their new migraine launches, but Teva's Ajovy was left out in the cold.

In a lawsuit this week, Minnesota AG Lori Swanson alleged that insulin list prices hikes from Sanofi, Novo Nordisk and Eli Lilly are "deceptive."

As a shortage of epinephrine pens continues to grip the U.K., authorities are extending the expiration dates on a second injector.

The FDA approved Pfizer's PARP inhibitor, Talzenna, in breast cancer, but its ability to grab share depends on expanding the market.

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

The FDA, which banned products from a South Korean sterile manufacturer last spring, has now followed up with a warning letter.

Merck is joining the chief digital officer parade, hiring Jim Scholefield from Nike to head up IT and digital strategy—not to mention cybersecurity.